Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NBIX – Neurocrine Biosciences, Inc.

Float Short %

3.46

Margin Of Safety %

-15

Put/Call OI Ratio

1.12

EPS Next Q Diff

-0.05

EPS Last/This Y

3.49

EPS This/Next Y

2.26

Price

154.99

Target Price

176.66

Analyst Recom

1.33

Performance Q

7.51

Relative Volume

1.52

Beta

0.28

Ticker: NBIX




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-10NBIX149.940.952.3511716
2025-11-11NBIX147.330.982.7311906
2025-11-12NBIX146.840.972.2011916
2025-11-13NBIX144.140.970.0111906
2025-11-14NBIX144.811.020.2111591
2025-11-17NBIX143.521.030.4011565
2025-11-18NBIX139.151.030.3611574
2025-11-19NBIX138.021.051.3511470
2025-11-20NBIX138.981.045.5112179
2025-11-21NBIX141.881.031.5812146
2025-11-24NBIX140.651.250.008335
2025-11-25NBIX143.561.080.168937
2025-11-26NBIX151.621.070.038964
2025-12-01NBIX150.981.080.389159
2025-12-02NBIX152.51.090.099197
2025-12-03NBIX151.851.060.059328
2025-12-04NBIX154.251.050.009396
2025-12-05NBIX155.511.041.799406
2025-12-08NBIX154.951.121.439903
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-10NBIX150.0242.7467.76.89
2025-11-11NBIX147.2942.7464.36.89
2025-11-12NBIX146.8043.7481.46.90
2025-11-13NBIX144.0743.7463.76.90
2025-11-14NBIX144.8042.7490.46.89
2025-11-17NBIX143.5642.7474.76.89
2025-11-18NBIX138.6442.7446.06.89
2025-11-19NBIX138.0642.7480.36.89
2025-11-20NBIX138.9542.7492.26.89
2025-11-21NBIX141.8242.7507.96.89
2025-11-24NBIX141.2542.7480.76.89
2025-11-25NBIX143.5342.7502.76.89
2025-11-26NBIX151.5742.7547.76.89
2025-12-01NBIX150.8742.7475.56.89
2025-12-02NBIX152.4842.7496.66.89
2025-12-03NBIX151.9642.7481.16.89
2025-12-04NBIX154.2342.7501.66.89
2025-12-05NBIX155.5142.7494.36.89
2025-12-08NBIX154.9942.7- 6.89
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-10NBIX-7.373.134.50
2025-11-11NBIX-7.373.134.50
2025-11-12NBIX-7.373.134.24
2025-11-13NBIX-7.373.134.24
2025-11-14NBIX-7.373.134.24
2025-11-17NBIX-7.375.534.24
2025-11-18NBIX-7.375.534.24
2025-11-19NBIX-7.375.534.24
2025-11-20NBIX-7.375.534.24
2025-11-21NBIX-7.375.534.24
2025-11-24NBIX-7.37-1.264.24
2025-11-25NBIX-7.55-1.264.24
2025-11-26NBIX-8.03-1.263.46
2025-12-01NBIX-7.72-1.303.46
2025-12-02NBIX-7.91-1.303.46
2025-12-03NBIX-7.91-1.303.46
2025-12-04NBIX-7.91-1.303.46
2025-12-05NBIX-8.40-1.303.46
2025-12-08NBIX-8.40-1.253.46
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

2.04

Avg. EPS Est. Current Quarter

2.41

Avg. EPS Est. Next Quarter

1.99

Insider Transactions

-8.4

Institutional Transactions

-1.25

Beta

0.28

Average Sales Estimate Current Quarter

805

Average Sales Estimate Next Quarter

773

Fair Value

131.4

Quality Score

79

Growth Score

99

Sentiment Score

81

Actual DrawDown %

1.9

Max Drawdown 5-Year %

-42.9

Target Price

176.66

P/E

37.01

Forward P/E

21.89

PEG

1.03

P/S

5.76

P/B

5.14

P/Free Cash Flow

26.06

EPS

4.19

Average EPS Est. Cur. Y​

6.89

EPS Next Y. (Est.)

9.15

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

15.95

Relative Volume

1.52

Return on Equity vs Sector %

-12.6

Return on Equity vs Industry %

6.8

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Neurocrine Biosciences, Inc.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1800
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
stock quote shares NBIX – Neurocrine Biosciences, Inc. Stock Price stock today
news today NBIX – Neurocrine Biosciences, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch NBIX – Neurocrine Biosciences, Inc. yahoo finance google finance
stock history NBIX – Neurocrine Biosciences, Inc. invest stock market
stock prices NBIX premarket after hours
ticker NBIX fair value insiders trading